What is AI's role in synthesizing compounds? Peter Madrid explains in his latest article The Promise and Peril of AI in the Physical World, in PharmaExec: pharmexec.com/view/the-promi… #AI #DrugDiscovery

Our co-founder and head of scientific development Peter Madrid explores new therapeutic approaches for K-Ras: “We're getting even closer to cracking K-Ras driven cancers… medium.com/synfini/ai-the-hu… #cancerresearch #drugdiscovery

Testing in humans in clinical trials and the regulatory approval process itself are candidates for technology solutions where AI plays a role. Nathan Collins looks at the evolving role of AI in early drug discovery: appliedclinicaltrialsonline.… #AI #drugdiscovery

.@DrugDiscoverDev covers Synfini and the promise of LCMs in "From Silicon Valley to the lab of tomorrow: Synfini’s leap to large chemistry models" drugdiscoverytrends.com/from… #AI #DrugDiscovery

Excited to take part in the Gladstone Institutes Industry Partnership Forum 2023. gladstone.org/events/industr…. Connect with us Tuesday Oct. 24 during our session "Virtual and Physical, Closed-Loop Discovery with the Synfini Platform," or contact us to learn more.

Synfini’s CEO in @thecubetv: “At Synfini, neuro-symbolic AI accelerates the generation of molecular compound leads and their optimization for use by at least 50% & with at least a 40% reduction in research and dev costs." siliconangle.com/2023/09/26/…

Synfini has the ability to immediately transform the $21BN drug discovery industry with a completely new approach, unparalleled chemistry data, and a unique platform that dramatically reduces the time-to-discovery of novel therapeutics. Intrigued? Read on: synfini.com/press-releases/s…